This is a draft cheat sheet. It is a work in progress and is not finished yet.
MONA
Morphine |
Oxygen |
Nitroglycerin |
Aspirin |
Antiplatelet
Dual antiplatelet therapy is highly recommended in the treatment of STEMI to support primary PCI and fibrinolytic treatment strategies |
aspirin |
P2Y12 Inhibitor
Administered as early as possible or at the time of PCI |
clopidogrel (Plavix) |
prasugrel (Effient) |
ticagrelor (Brilinta) |
Anticoagulants
Anticoagulation therapy should also be initiated with either PCI or fibrinolytic therapy for the treatment of STEMI. Treatment should be given for a minimum of 48 hours and up to eight days |
bivalirudin (Angiomax) |
enoxaparin (Lovenox) |
fondaparinux (Arixtra) |
unfractionated heparin |
Glycoprotein IIb/IIIa inhibitors
Have shown benefit when used during PCI in persons with STEMI and as an adjunct to PCI in persons with NSTE-ACS; however, triple antiplatelet therapy has been associated with an increased risk of bleeding |
tirofiban (Aggrastat) |
eptifibatide (Integrilin) |
abciximab (Reopro) |
|
|
Beta Blockers
Started within 24 hours in patients with STEMI |
carvedilol |
metoprolol |
ACE Inhibitors
Should be administered within the first 24 hours to all patients with heart failure, STEMI with anterior location, or ejection fraction less than 40%, in the absence of contraindications to therapy |
captopril |
lisinopril |
Statin
Continuing or initiating high-intensity statin therapy is recommended, even in patients with baseline low-density lipoprotein cholesterol levels less than 70 mg per dL |
atorvastatin |
|
|
Discharge Medications
DAPT - aspirin + P2Y12-i (atleast a year for stent) |
anticoagulants (up to 8 days or as directed by provider) |
beta blocker (indefinitely) |
ACEi/ARB (indefinitely) |
high intensity statin (indefinitely) |
nitroglycerin (PRN) |
|
